Raveau-Landon C, Bousser M G
Laboratoires Astra France, Tour Avenir Quest, Nanterre.
Presse Med. 1988 Oct 15;17(35):1805-9.
The effectiveness of metoprolol as a prophylactic treatment of migraine was investigated in double-blind comparative trials involving more than 500 patients. In two trials using a slow-release preparation and a dose of 200 mg per day, metoprolol proved significantly better than a placebo and as effective as propranolol 160 mg/day or flunarizine 10 mg/day. At the dose of 100 mg per day metoprolol was significantly more effective than clonidine and clomipramine and not different from a placebo, propranolol 80 mg/day or pizotifen 1.5 mg/day. It is concluded that metoprolol is useful as prophylactic treatment of migraine and ranks among the main drugs used for the same purpose, such as propranolol and pizotifen.
在涉及500多名患者的双盲对照试验中,对美托洛尔作为偏头痛预防性治疗的有效性进行了研究。在两项使用缓释制剂且每日剂量为200毫克的试验中,美托洛尔被证明明显优于安慰剂,且与每日160毫克的普萘洛尔或每日10毫克的氟桂利嗪效果相当。在每日100毫克的剂量下,美托洛尔比可乐定和氯米帕明明显更有效,且与安慰剂、每日80毫克的普萘洛尔或每日1.5毫克的苯噻啶无差异。得出的结论是,美托洛尔作为偏头痛的预防性治疗是有用的,并且位列用于同一目的的主要药物之中,如普萘洛尔和苯噻啶。